Compare ADUS & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADUS | IMNM |
|---|---|---|
| Founded | 1979 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.5B |
| IPO Year | 2009 | 2020 |
| Metric | ADUS | IMNM |
|---|---|---|
| Price | $117.59 | $26.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 10 |
| Target Price | ★ $133.78 | $32.80 |
| AVG Volume (30 Days) | 211.9K | ★ 991.6K |
| Earning Date | 05-04-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.40 | ★ 51.40 |
| EPS | ★ 2.85 | N/A |
| Revenue | N/A | ★ $6,941,000.00 |
| Revenue This Year | $9.17 | N/A |
| Revenue Next Year | $4.70 | $1,127.34 |
| P/E Ratio | $41.42 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $87.95 | $8.67 |
| 52 Week High | $124.44 | $28.04 |
| Indicator | ADUS | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 58.70 | 64.01 |
| Support Level | $106.22 | $19.28 |
| Resistance Level | $120.27 | $27.14 |
| Average True Range (ATR) | 3.57 | 1.42 |
| MACD | -0.53 | 0.30 |
| Stochastic Oscillator | 69.79 | 67.08 |
Addus HomeCare Corp is engaged in the provision of in-home care services. The Company has three reportable segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living, mainly to the elderly, chronically ill, and disabled individuals. The Hospice segment provides physical, emotional, and spiritual care for terminally ill patients and their families. The Home Health segment provides medical services to individuals requiring care during illness or recovery. It generates the majority of its revenue from the Personal Care segment.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.